



## **Philadelphia Business Journal Recognizes Molecular Targeting Technologies, Inc. for 2013 Innovation Award**

February 28, 2014, West Chester, PA: Molecular Targeting Technologies, Inc. (MTTI) received the 2013 Innovation Finalist Award from Philadelphia Business Journal. This award is in recognition of MTTI's abilities in raising sufficient funding to develop innovative technologies from cancer to cardiovascular diseases.

The 2013 Innovation Awards celebrate companies in health care and science that continue to reshape the medical industry in Greater Philadelphia and New Jersey. Philadelphia Business Journal and presenting sponsor United Healthcare recognize health care and life science leaders in the 2013 Innovation Awards.

### **Molecular Targeting Technologies, Inc.**

Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company primarily focused on the identification, evaluation, acquisition and development of novel technologies for diagnosis and treatment of human diseases. MTTI has licensed several proprietary technologies that allow targeting of glioma and prostate cancers as well as stroke and myocardial infarction. MTTI is also advancing a therapeutic human monoclonal antibody in China for Rabies post-exposure prophylaxis and a vaccine technology for development of a Botulinum neurotoxin vaccine and a potent human rabies vaccine. In addition, MTTI is building a research reagents business and currently offers a range of innovative fluorescence based products for in vitro and in vivo research applications. Please visit our website: [www.mtarget.com](http://www.mtarget.com) for more information.

### **Contacts:**

Chris Pak, e-mail: [cpak@mtarget.com](mailto:cpak@mtarget.com); Tel: (610) 738-7938